DCPH - デシフィラ・ファ―マシュ―ティカルズ （Deciphera Pharmaceuticals Inc.） デシフィラ・ファ―マシュ―ティカルズDCPHのチャート
DCPHの企業情報
| symbol | DCPH |
|---|---|
| 会社名 | Deciphera Pharmaceuticals Inc （デシフィラ・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 デシフェラ・ファーマシューティカルズ(Deciphera Pharmaceuticals Inc.)は臨床段階の製薬会社である。同社はがん患者の生活を改善するための薬物を開発している。同社の薬剤候補には、DCC-2618、DCC-3014およびレバスチニブが含まれる。独自のキナーゼスイッチ制御阻害剤プラットフォームは、キナーゼの活性化を阻害する。DCC-2618はDCC-2618は、消化管間質腫瘍（GIST）、進行性全身性肥満細胞症（ASM）、神経膠芽細胞腫（GBM）およびpan-KITまたはPDGFRアルファによって駆動される他の固形腫瘍の治療用経口投与キナーゼスイッチ制御阻害剤である。DCC-3014は、コロニー刺激因子受容体1（CSF1R）の経口投与された強力かつ高度に選択的な阻害剤である。レバスチニブは、経口的に投与され、TIE2免疫キナーゼの強力で選択的な阻害剤である。レバスチニブは、TIE2のスイッチポケットに強力に結合し、阻害スイッチを安定化させ、活性化スイッチを変位させてTIE2シグナル伝達を遮断する。 デシフィラ・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、がん治療の反応速度を制限する薬剤耐性のメカニズムを研究し、がん患者の生活を改善する新薬の開発に従事する。同社独自のキナ―ゼスイッチ制御阻害プラットフォ―ムによる小分子薬物候補は、多くのがんが転移することを防ぐために開発される。本社所在地はマサチュ―セッツ州ウォルサム。 Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. The Company is leveraging its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from its platform in clinical studies, QINLOCK is Deciphera's FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Canada and Australia. |
| 本社所在地 | 500 Totten Pond Road Waltham MA 02451 USA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | +1 781-209-6400 |
| 設立年月日 | 42948 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2017年 |
| 従業員数 | － |
| url | www.deciphera.com |
| nasdaq_url | https://www.nasdaq.com/symbol/dcph |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -76.68100 |
| 終値（lastsale） | 30.84 |
| 時価総額（marketcap） | 1161348078.84 |
| 時価総額 | 時価総額（百万ドル） 1182.06 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 836.92100 |
| 当期純利益 | 当期純利益（百万ドル） -75.07000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Deciphera Pharmaceuticals Inc revenues was not reported. Net loss increased from $18.3M to $43.1M. Higher net loss reflects Research and development increase from $13.8M to $33M (expense) General and administrative increase of 97% to $7.2M (expense) Share-based compensation in Selling Gen increase from $672K to $2.3M (expense). |
DCPHのテクニカル分析
DCPHのニュース
Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences 2022/06/02 11:00:00 Business Wire
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that members of the management team will participate in fireside chats at the following investor conferences: Jefferies Healthcare Conference on June 9, 2022 at 10:00 AM ET in New York, NY JMP Securities Life Sciences Conference on June 15, 2022 at 10:00 AM ET in New York, NY A live webcast of both events will be available on the “Events and Presentations” page in the “Investors” section of the Compa
Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH) Could See Prices Soar In The Coming Months 2022/05/10 13:30:00 Marketing Sentinel
In the last trading session, 1.12 million shares of the Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) were traded, and its beta was 1.40. Most recently the company’s share price was $9.11, and it changed around -$0.57 or -5.89% from the last close, which brings the market valuation of the company to $662.48M. DCPH currently trades at a … Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH) Could See Prices Soar In The Coming Months Read More »
Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steven Hoerter on Q1 2022 Results - Earnings Call Transcript 2022/05/08 09:22:06 Seeking Alpha
Deciphera Pharmaceuticals, Inc. (NASDAQ:NASDAQ:DCPH) Q1 2022 Earnings Conference Call May 04, 2022, 08:00 ET Company Participants Margarida Duarte - SVP & Head, International Steven…
Deciphera Pharmaceuticals GAAP EPS of -$0.80 beats by $0.05, revenue of $29.2M beats by $2.03M 2022/05/04 11:13:45 Seeking Alpha
Deciphera Pharmaceuticals press release (DCPH): Q1 GAAP EPS of -$0.80 beats by $0.05.Revenue of $29.2M (+15.9% Y/Y) beats by $2.03M.
Deciphera Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results 2022/05/04 11:00:00 Business Wire
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the first quarter ended March 31, 2022, and provided a corporate update. “We have made significant progress on our 2022 goals so far this year, demonstrating our commercial success with QINLOCK®, strengthening our balance sheet, and rapidly advancing our potential best-in-class and first-in-class clinical-stage pipeline,” said Steve Hoerter, President and Chief Executive Officer
H.C. Wainwright Stick to Their Buy Rating for Deciphera Pharmaceuticals By Investing.com 2021/08/04 10:26:39 Investing.com
H.C. Wainwright Stick to Their Buy Rating for Deciphera Pharmaceuticals
Is it time to Buy before this weeks earning report Deciphera Pharmaceuticals (NASDAQ:DCPH) 2021/08/03 12:51:00 Stock Market Daily
Earnings results for Deciphera Pharmaceuticals , Analyst Opinion on Deciphera Pharmaceuticals , Earnings and Valuation of (NASDAQ:DCPH), Stock market Insights & financial analysis, Best stock to invest, Investment Idea, The post Is it time to Buy before this weeks earning report Deciphera Pharmaceuticals (NASDAQ:DCPH) appeared first on .
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts 2021/07/27 11:48:32 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI ) (IPOed Thursday) Arvinas, Inc. (NASDAQ: ARVN ) BioNTech SE (NASDAQ: BNTX ) ( disclosed plans to make mRNA vaccine for malaria by 2022) Cassava Sciences, Inc. (NASDAQ: SAVA ) (announced positive data for SavaDx, an investigational diagnostic/biomarker to detect Alzheimer''s disease with a simple blood test) Eli Lilly and Company (NYSE: LLY ) Moderna, Inc. (NASDAQ: MRNA ) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE ) NanoVibronix, Inc. (NASDAQ: NAOV ) (announced first shipment of its next generation pain management device, PainShield Plus) Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) Sight Sciences, Inc. (NASDAQ: SGHT ) (IPOed July 15) Translate Bio, Inc. (NASDAQ: TBIO ) (moved on positive analyst action) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 26) 23andMe Holding Co. (NASDAQ: ME ) AbCellera Biologics Inc.
Global Tyrosine Protein Kinase Lyn Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: AB Science SA, Pfizer Inc., Boehringer Ingelheim GmbH, Deciphera Pharmaceuticals, LLC 2021/07/23 22:10:51 Jumbo News
The report on Global Tyrosine Protein Kinase Lyn Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a []
Deciphera Announces First Patient Treated in Phase 1 Study of DCC-3116 in Patients with Advanced or Metastatic Tumors with a Mutant RAS or RAF Gene 2021/06/30 20:01:00 Finanzen AT
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced dose administration for the first
Deciphera Pharmaceuticals (NASDAQ-DCPH) Is In A Good Position To Deliver On Growth Plans 2021/06/24 06:57:17 Yahoo Finance
Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans Yahoo Finance
Deciphera Pharmaceuticals posts data from cancer studies at ASCO21 2021/06/04 13:47:01 Seeking Alpha
Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences 2021/05/27 00:00:00 BioSpace
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in fireside chats at the following investor conferences: Jefferies Virtual Healthcare Conference on June 3, 2021 at 1:30 PM ET JMP Securities Life Sciences Conference on June 16, 2021 at 4:00 PM ET